Jacobio Receives CDE Approval for Glecirasib's Pancreatic Cancer Pivotal Study in China
- Written by PR Newswire
BEIJING, SHANGHAI and BOSTON, July 4, 2023 /PRNewswire/ -- Jacobio Pharma (1167.HK), a clinical-stage oncology company drugging the undruggable targets, today announced its novel KRAS G12C inhibitor glecirasib's pivotal study for pancreatic cancer has been approved from CDE (Center for Drug Evaluation), which became the first global pancreatic...
Read more: Jacobio Receives CDE Approval for Glecirasib's Pancreatic Cancer Pivotal Study in China